You are here: Industry Insights > faricimab

News List

FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) firstwordpharma
August 06, 2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment.
FDA accepts application for Roche’s Faricimab expresspharma
July 30, 2021
If approved, Faricimab would be the first and only medicine designed to target two distinct pathways that drive retinal diseases that can cause vision loss.
Roche reports 3% increase in group sales in first quarter of 2021 pharmaceutical-technology
April 23, 2021
Roche has reported a 3% increase in group sales to $16.247bn (CHF14.9bn) in the first quarter of 2021 at constant exchange rates.
Roche’s vision loss therapy faricimab extends time between treatments by up to four months pharmatimes
February 20, 2021
Roche’s investigational bispecific antibody faricimab has been found to extend the time between treatments by up to four months in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Roche’s faricimab hits primary endpoint in wet AMD studies pharmatimes
January 27, 2021
Roche’s investigational bispecific antibody faricimab has hit the primary endpoint in two Phase III studies in people living with neovascular or wet age-related macular degeneration (nAMD).
Roche’s faricimab hits the mark in diabetic macular edema study pharmatimes
December 22, 2020
Swiss pharma company Roche has announced that its investigational bispecific antibody faricimab met the primary endpoint across two phase III studies in diabetic macular edema (DME), a leading cause of vision loss.